Former pharmaceutical executive Martin Shkreli has congratulated a group of Australian students who reproduced the active ingredient for a lifesaving, anti-parasitic drug at the center of a drug-price controversy involving his former company.
The students from Sydney Grammar School drew global media attention this week after they said they had produced the drug Daraprim for about $2 a dose, a fraction of the current list price of $750 per dose.
Shkreli is a former chief executive of Turing Pharmaceuticals, where he sparked outrage among patients and U.S. lawmakers for raising the price of Daraprim by more than 5,000 percent.
Yes, before Marty got ahold of Turing, the price of a dose was $13.50 - high, but do-able. There's a reason why Marty is a former executive of several different companies:
Shkreli stepped down as Turing's chief executive in December 2015 after being indicted on charges that he engaged in a Ponzi-like scheme at a hedge fund and Retrophin Inc, a company he once headed.
Basically, he's another Gordon Gekko: "Greed is good". He's no ham sandwich, but a grand jury did indict him. Thankfully, the high-school students have demonstrated that good pharmacology can be done without big pharma.